Back to top

CleanCap® technology

Accelerate therapeutic and vaccine development with an effective mRNA capping strategy

The 5’ cap structure is integral to the stability, expression, and immunogenicity of an mRNA product, but generating a synthetic cap can present manufacturing challenges and inefficiencies. The TriLink® proprietary CleanCap® technology is a one-pot solution which produces an optimal Cap1 structure with over 95% efficiency. Co-transcriptional capping with CleanCap® analogs overcomes the limitations of legacy capping methods, helping you bring your mRNA vaccine or therapeutic to market faster.

TriLink_MOA_0-19_Cap_720x325

Streamline mRNA manufacturing processes and reduce costs

As momentum grows in the mRNA therapeutic and vaccine pipeline, development timelines are critical in the race to reach the market. Leveraging the CleanCap® co-transcriptional capping solution, you can cut mRNA therapeutic production processes by nearly one week and reduce overall manufacturing costs 20-40% lower than other capping methods.

By streamlining manufacturing, CleanCap® technology helps to ensure your mRNA program meets key development deadlines and cost-saving targets, increasing your likelihood of success in the path to the clinic.

EstimatedManufacturingTime-rs
cost

Discover the CleanCap® technology difference

While an enzymatic capping reaction requires two separate bioreactor reactions to synthesize and cap mRNA, CleanCap® technology produces a Cap1 structure in a single co-transcriptional reaction. With only one purification and bioreactor step, this simplified process eliminates the need for additional reagents and enzymes while contributing to a high expected yield. 

CleanCap_Chart_720x575

Choose the right CleanCap® analog for your application

We offer a robust portfolio of CleanCap® cap analogs for use in the discovery or GMP manufacturing of vaccines, cell therapies, gene replacement therapies, and more, ensuring an optimal mRNA capping strategy to help maximize mRNA potency and subsequent protein expression.

  • Designed specifically for self-amplifying RNA applications
  • Naturally occurring 5' N7-Methylguanosine structure and 2’ O-methylation on the first base
  • Yields the authentic alphavirus 5’ virus cap structure
  • Naturally occurring 5' N7-Methylguanosine structure and 2’ O-methylation on the first base
  • Provides up to 98% capping efficiency
  • Modification of CleanCap® AG which includes the 2’ O-methylation on the first base and 5' N7-Methylguanosine structure with an additional O-methylation on the 3’ position of the cap
  • Provides up to 98% capping efficiency
  • Combined modifications of CleanCap® AG 3’OMe and a methylation of position 6 of the first adenosine
  • Provides up to 98% capping efficiency
  • Higher protein yield, up to 30% more than other CleanCap® analogs and capping methods
  • Increase potency of your mRNA drug substance

Related products and services

Modified NTPs

The extensive TriLink® catalog of modified nucleoside triphosphates, available from RUO to GMP-grade, provides the highest quality NTPs for any application.

Novasep_Hipersep
Largescale_NTP_Synthesis

N1-Methylpseudouridine-5’-Triphosphate

N1-Methylpseudouridine-5'-Triphosphate, available in both GMP- and RUO-grade, is a modified NTP for incorporation into messenger RNAs (mRNA) using T7 RNA Polymerase.

mRNA synthesis and manufacturing services

Our manufacturing processes are fully customizable and scalable to support your needs for discovery, preclinical, and clinical projects.

Akta_ready

Discover how to enhance your mRNA production today

Ready to elevate your mRNA therapeutic development process?
Talk to our team about what may be the best option for you. Fill out the form below to get started.

Request A Quote for CleanCap

Clean Cap
Privacy policy
TriLink BioTechnologies does not sell or distribute your information to 3rd parties. For more information, please refer to our Privacy Policy.